Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022

Rhea-AI Summary

Iveric Bio (NASDAQ: ISEE) will report its second quarter 2022 financial results on July 26, 2022, followed by a conference call at 8:00 a.m. ET. The call will include a discussion of financial results and a general business update. Interested participants can join the call by dialing 1-888-317-6003 (USA) or 1-412-317-6061 (International), using passcode 0932671. A replay will be available after the call. Iveric Bio focuses on developing treatments for retinal diseases, addressing significant unmet medical needs.

Positive

• Scheduled report of Q2 2022 financial results could indicate transparency and engagement with investors.
• Focus on retinal disease treatments aligns with significant unmet medical needs, potentially driving market interest.

Negative

• None.

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 0932671. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the live call for two weeks. The replay number is 1-877-344-7529 (USA Toll Free), passcode 6585313.

About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements
Any statements in this press release about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release. Iveric Bio anticipates that subsequent events and developments will cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220721006007/en/

Investor Contact:

Kathy Galante

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com

Media Contact:

Jeannie Neufeld

Senior Director, Public Relations & Communications

jeannie.neufeld@ivericbio.com

Source: IVERIC bio, Inc.

FAQ

When will Iveric Bio report its second quarter 2022 financial results?

Iveric Bio will report its second quarter 2022 financial results on July 26, 2022.

What time will the Iveric Bio conference call take place?

The Iveric Bio conference call will take place at 8:00 a.m. Eastern Time.

How can I participate in the Iveric Bio conference call?

To participate in the Iveric Bio conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International) and use passcode 0932671.

What is the focus of Iveric Bio as a biopharmaceutical company?

Iveric Bio focuses on the discovery and development of novel treatments for retinal diseases.